Attovia Therapeutics Announces $90 Million Series C Financing to Advance ATTOBODY-based Programs through Clinical Proof of Concept
Series C round led by Deep Track Capital with participation from additional new and existing investors Financing will fund early-to-mid-stage clinical studies for ATTO-1310 in chronic pruritus and ATTO-3712 in atopic dermatitis, and multiple earlier-stage multi-specific programs SAN CARLOS, Calif., April 15, 2025 (GLOBE NEWSWIRE) — Attovia Therapeutics, a privately-held, clinical-stage biopharma company developing treatments […]
